Kiniksa Pharmaceuticals International, plc
For the period ended Dec 31, 2025. Filed Feb 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 24, 2026
KNSA$98.76+5.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Shareholders’ Equity
(In thousands, except share amounts)
| | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · Ordinary Shares · · Additional · · Accumulated · · · · · Total | ||||||||||||||||||
| · · · (Class A, B, A1 and B1) · · Paid-In · · Other Comprehensive · · Accumulated · · Shareholders' | ||||||||||||||||||
| · · Shares · · Amount · · Capital · · Income (Loss) · · Deficit · · Equity | ||||||||||||||||||
| Balances at December 31, 2022 | | | 69,697,503 | | $19 | | $888,120 | | $44 | | $(492,034) | | $396,149 | |||||
| Issuance of Class A ordinary shares under incentive award plans and employee share purchase plan | | | 763,114 | | | 1 | | | 1,494 | | | — | | | — | | | 1,495 |
| Share-based compensation expense | | | — | | | — | | | 27,149 | | | — | | | — | | | 27,149 |
| Unrealized loss on short-term investments and currency translation adjustments | | | — | | | — | | | — | | | (38) | | | — | | | (38) |
| Net income | | | — | | | — | | | — | | | — | | | 14,084 | | | 14,084 |
| Balances at December 31, 2023 | | | 70,460,617 | | $20 | | $916,763 | | $6 | | $(477,950) | | $438,839 | |||||
| Issuance of Class A ordinary shares under incentive award plans and employee share purchase plan | | | 2,055,442 | | | — | | | 12,266 | | | — | | | — | | | 12,266 |
| Share-based compensation expense | | | — | | | — | | | 30,693 | | | — | | | — | | | 30,693 |
| Unrealized loss on short-term investments and currency translation adjustments | | | — | | | — | | | — | | | (169) | | | — | | | (169) |
| Net loss | | | — | | | — | | | — | | | — | | | (43,193) | | | (43,193) |
| Balances at December 31, 2024 | | | 72,516,059 | | $20 | | $959,722 | | $(163) | | $(521,143) | | $438,436 | |||||
| Issuance of Class A ordinary shares under incentive award plans and employee share purchase plan | | | 3,778,105 | | | 1 | | | 33,023 | | | — | | | — | | | 33,024 |
| Share-based compensation expense | | | — | | | — | | | 37,003 | | | — | | | — | | | 37,003 |
| Unrealized gain on short-term investments and currency translation adjustments | | | — | | | — | | | — | | | 138 | | | — | | | 138 |
| Net income | | | — | | | — | | | — | | | — | | | 59,005 | | | 59,005 |
| Balances at December 31, 2025 | | | 76,294,164 | | $21 | | $1,029,748 | | $(25) | | $(462,138) | | $567,606 | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.